Immunohistochemical studies on expression of human vascular smooth muscle myosin heavy chain isoforms in normal mammary glands, benign mammary disorders and mammary carcinomas

Pathology International

Volumn 48, Issue 6, 1998, Pages 433-439

  Ohyabu, Ikuya ^a   Takasaki, Takashi ^a   Akiba, Suminori ^a   Nomura, Satoru ^b   Enokizono, Nobumasa ^b   Sagara, Yoshiatsu ^b   Hiroi, Junko ^c   Nagai, Ryozo ^d   Yoshida, Hiroki ^a  

^a KAGOSHIMA UNIVERSITY   (Japan)

^b SAGARA HOSPITAL   (Japan)

^c UNIVERSITY OF TOKYO   (Japan)

^d GUNMA UNIVERSITY   (Japan)

Author keywords

Immunohistochemistry; Mammary carcinoma; Mammary disorder; Mammary gland; Myosin

Indexed keywords

ESTROGEN RECEPTOR; MYOSIN HEAVY CHAIN; ONCOPROTEIN; PROGESTERONE RECEPTOR;

ADOLESCENT; ADULT; AGE; ARTICLE; BREAST CARCINOMA; BREAST DISEASE; BREAST FIBROADENOMA; CANCER GRADING; CONTROLLED STUDY; CYSTOSARCOMA PHYLLOIDES; CYTOPLASM; FEMALE; FIBROCYSTIC BREAST DISEASE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MULTIVARIATE ANALYSIS; MYOEPITHELIUM CELL; ONCOGENE C ERB; PRIORITY JOURNAL; PROGNOSIS; TUMOR VOLUME; VASCULAR SMOOTH MUSCLE;

EID: 0031811853     PISSN: 13205463     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1440-1827.1998.tb03929.x     Document Type: Article

References (47)

1. Rovner AS, Thompson MM, Murphy RA. Two different heavy chains are found in smooth muscle myosin. Am. J. Physiol. 1986; 19: C861-C870.
2. Nagai R, Larson DT, Periasamy M. Characterization of a mammalian smooth muscle myosin heavy chain cDNA clone and its expression in various smooth muscle types. Proc. Natl Acad. Sci. USA 1988; 85: 1047-1051.
3. Nagai R, Kuro-o M, Babij P, Periasamy M. Identification of two types of smooth muscle myosin heavy chain isoforms by cDNA cloning and immunoblot analysis. J. Biol. Chem. 1989; 264: 9734-9737.
4. Kuro-o M, Nagai R, Tsuchimochi H et al. Developmentally regulated expression of vascular smooth muscle myosin heavy chain isoforms. J. Biol. Chem. 1989; 264: 18272-18275.
5. Kuro-o M, Nagai R, Nakahata K et al. cDNA cloning of a myosin heavy chain isoform in embryonic smooth muscle and its expression during vascular development and in arteriosclerosis. J. Biol. Chem. 1991; 266: 3768-3773.
6. Babij P, Periasamy M. Myosin heavy chain isoform diversity in smooth muscle is produced by differential RNA processing. J. Mol. Biol. 1989; 210: 673-679.
7. Raines EW, Ross R. Smooth muscle cells and the pathogenesis of the lesion of atherosclerosis. Br. Heart J. 1993; 69: S30-S37.
8. Ross R. The pathogenesis of atherosclerosis: A perspective for the 1990s. Nature 1993; 362: 801-809.
9. Katsuragawa Y, Yanagisawa M, Inoue A, Masaki T. Two distinct non-muscle myosin-heavy-chains mRNAs are differentially expressed in the various chicken tissues. Eur. J. Biochem. 1989; 184: 611-616.
10. Kawamoto S, Adelstein RS. Chicken nonmuscle myosin heavy chains: Differential expression of two mRNAs and evidence for two different polypeptides. J. Cell Biol. 1991; 112: 915-924.
11. Simons M, Wang M, Macbride OW et al. Human nonmuscle myosin heavy chains are encoded by two genes located on different chromosomes. Circ. Res. 1991; 69: 530-539.
12. Aikawa M, Sivam PN, Kuro-o M et al. Human smooth muscle myosin heavy chain isoforms as molecular markers for vascular development and atherosclerosis. Circ. Res. 1993; 73: 1000-1012.
13. Kim HS, Aikawa M, Kimura K et al. Ductus arteriosus: Advanced differentiation of smooth muscle cells demonstrated by myosin heavy chain isoform expression in rabbits. Circulation 1993; 88 (Part 1): 1804-1810.
14. Aikawa M, Kim HS, Kuro-o M et al. Phenotypic modulation of smooth muscle cells during progression of human atherosclerosis as determined by altered expression of myosin heavy chain isoforms. Ann. N. Y. Acad. Sci. 1995; 748: 578-585.
15. Chiavegato A, Piallat MLB, Amore E, Sartore S, Gabbiani G. Expression of myosin heavy chain isoforms in mammary epithelial cells and in myofibroblasts from different fibrotic settings during neoplasia. Virchows Arch. 1995; 426: 77-86.
16. Gallager HS, Martin JE. Early phases in the development of breast cancer. Cancer 1969; 24: 1170-1178.
17. Goldenberg VE, Goldenberg NS, Sommers SC. Comparative ultrastructure of atypical ductal hyperplasia, intraductal carcinoma, and infiltrating ductal carcinoma of the breast. Cancer 1969; 24: 1152-1169.
18. Hamperl H. The myoepithelia (myoepithelial cells). Normal state, regressive change, hyperplasia, tumors. Curr. Top. Pathol. 1970; 53: 161-220.
19. Kraus FT, Neubecker RD. The differential diagnosis of papillary tumors of the breast. Cancer 1962; 15: 444-455.
20. Lazard D, Sastre X, Frid MG, Glukhova MA, Thiery JP, Koteliansky VE. Expression of smooth muscle-specific proteins in myoepithelium and stromal myofibroblasts of normal and malignant human breast tissue. Proc. Natl Acad. Sci. USA 1993; 90: 999-1003.
21. Gabbiani G, Brassert JC, Schneeberger JC, Kapanci Y, Trenchev P, Holborow EJ. Contractile proteins in human cancer cells. Am. J. Pathol. 1976; 83: 457-474.
22. Clark GM, McGuire WL, Hubay CA, Pearson OH, Marshall JS. Progesterone receptors as a prognostic factor in stage II breast cancer. N. Engl. J. Med. 1983; 309: 1343-1347.
23. Clark GM, McGuire WL. Follow-up study of HER-2/neu amplification in primary breast cancer. Cancer Res. 1991; 51: 944-948.
24. Crowe JP, Gordon NH, Hubay CA, Pearson OH, Marshall JS, McGuire WL. The interaction of estrogen receptor status and race in predicting prognosis for stage I breast cancer patients. Surgery 1986; 100: 599-605.
25. Dawkins HJS, Robbins PD, Smith KL et al. What's new in breast cancer? Molecular perspectives of cancer development and the role of the oncogene c-erbB-2 in prognosis and disease. Pathol. Res. Pract. 1993; 189: 1233-1252.
26. Gullick WJ, Love SB, Wright C et al. c-erbB-2 protein overexpression in breast cancer is a risk factor in patients with involved and uninvolved lymph nodes. Br. J. Cancer 1991; 63: 434-438.
27. Nagai MA, Marques LA, Torloni H, Brentani MM. Genetic alterations in c-erbB-2 protooncogene as prognostic markers in human primary breast tumors. Oncology 1993; 50: 412-417.
28. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. Human breast cancer: Correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987; 235: 177-182.
29. Suzuki M, Okuyama T, Yoshikawa K et al. Overexpression of p53, c-erbB-2 and epidermal growth factor receptor in human breast carcinomas. Pathol. Int. 1996; 46: 46-53.
30. Tsuda H, Hirohashi S, Shimosato Y et al. Correlation between long-term survival in breast cancer patients and amplification of two putative oncogene-coamplification units: hst-1/int-2 and c-erbB-2/ear-1. Cancer Res. 1989; 49: 3104-3108.
31. Vecchione A. New and old in prognosis determination In Vivo 1993; 7: 623-626.
32. Wittliff JL. Steroid-hormone receptors in breast cancer. Cancer 1984; 53: 630-643.
33. World Health Organization. Histological Typing of Breast Tumors, 2nd edn. World Health Organization, Geneva, 1981; 18-19.
34. Bloom HGJ, Richardson WW. Histologic grading and prognosis in breast cancer. Br. J. Cancer 1957; 11: 655-669.
35. Aikawa M, Nagai R, Ueda M et al. Dynamic changes in smooth muscle phenotypes involved in human coronary atherosclerosis and post-PTCA restenosis as determined by the expression of myosin heavy chain isoforms. Circulation 1994; 90: I-511.
36. Simons M, Leclerc G, Safian RD, Isner JM, Weir L, Baim DS. Relation between activated smooth-muscle cells in coronary-artery lesions and restenosis after atherectomy. N. Engl. J. Med. 1993; 328: 608-613.
37. Nakamura T, Ebihara I, Fukui M et al. Effects of enalapril treatment on gene expression of smooth muscle myosin heavy chain isoforms in glomeruli of diabetic rats. Ren. Physiol. Biochem. 1995; 18: 183-190.
38. Nakamura T, Kimura K, Ebihara I et al. Glomerular expression of smooth-muscle myosin heavy-chain isoforms in aminonucleoside nephrosis in rats. Clin. Sci. Colch. 1995; 89: 45-52.
39. Simons M, Rosenberg RD. Antisense nonmuscle myosin heavy chain and c-myb oligonucleotides suppress smooth muscle cell proliferation in vitro. Circ. Res. 1992; 70: 835-843.
40. Fink Puches R, Smolle J. Cytoskeleton and motility: An immunohistological and computer simulation analysis of melanocytic skin tumors. J. Cutan. Pathol. 1993; 20: 130-136.
41. Ford HL, Zain SB. Interaction of metastasis associated Mts 1 protein with nonmuscle myosin. Oncogene 1995; 10: 1597-1605.
42. Leavitt J. Discovery and characterization of two novel human cancer-related proteins using two-dimensional gel electrophoresis. Electrophoresis 1994; 15: 345-357.
43. Macartney JC, Trevithick MA, Kricka L, Curran RC. Identification of myosin in human epithelial cancers with immunofluorescence. Lab. Inv. 1979; 41: 437-445.
44. Page DL. The clinical significance of mammary epithelial hyperplasia. The Breast 1992; 1: 3-7.
45. Kimura A, Nakashima S, Uda T et al. Heavy chain isoforms of non-muscle myosin in human tissues. Eur. J. Biochem. 1993; 213: 5-10.
46. Kimura A, Ikeda H, Yasuda S, Yamaguchi K, Tsuji T. Brain tissue identification based on myosin heavy chain isoforms. Int. J. Legal. Med. 1995; 107: 193-196.
47. Pereira H, Pinder SE, Sibbering DM et al. Pathological prognostic factors in breast cancer. IV: Should you be a typer or a grader? A comparative study of two histological prognostic features in operable breast carcinoma. Histopathology 1995; 27: 219-226.